▲ +128.90% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Nkarta in the last 3 months. The average price target is $64.00, with a high forecast of $81.00 and a low forecast of $41.00. The average price target represents a 128.90% upside from the last price of $27.96.
The current consensus among 5 investment analysts is to buy stock in Nkarta.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California.